Search Result
Results for "
anti-HBV
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N0056
-
-
-
- HY-149392
-
|
HBV
|
Infection
|
HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC50: 100 nM and 400 nM respectively) .
|
-
-
- HY-148782
-
|
HBV
|
Infection
|
HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC50 value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .
|
-
-
- HY-148783
-
|
HBV
|
Infection
|
HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC50 value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .
|
-
-
- HY-N8168
-
|
HBV
|
Infection
|
LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research .
|
-
-
- HY-N10404
-
|
HBV
|
Inflammation/Immunology
|
Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits HBV DNA replication and significantly decreases the level of supernatant HBV RNA with EC50 values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent .
|
-
-
- HY-N8153
-
-
-
- HY-131343
-
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .
|
-
-
- HY-N2988
-
-
-
- HY-145059
-
|
HBV
|
Infection
|
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM<EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15 .
|
-
-
- HY-148784
-
|
HBV
|
Infection
|
Neracorvir is a potent antiviral agent. Neracorvir exhibits anti-HBV activity .
|
-
-
- HY-P99608
-
|
HBV
|
Infection
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
-
-
- HY-P3601
-
FGF basic (1-24)
|
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research .
|
-
-
- HY-W018791
-
DDB
|
HBV
|
Infection
|
Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-HBV efficacy in research of chronic hepatitis B .
|
-
-
- HY-107026
-
|
HBV
|
Infection
|
Lagociclovir valactate is a prodrug of Lagociclovir (HY-14844). Lagociclovir valactate is an orally active anti-HBV agent .
|
-
-
- HY-N1323
-
|
HBV
|
Infection
|
Sanggenol P, a flavonoid, shows anti-HBV activity on HepG2.2.15 cell line in vitro .
|
-
-
- HY-139574
-
-
-
- HY-N2192
-
-
-
- HY-123336
-
|
HBV
|
Infection
|
Schisantherin C exhibits anti-HBV activity with potency against HBsAg and HBeAg secretion by 59.7% and 34.7% at 50μg/mL .
|
-
-
- HY-111003
-
NZ-4
|
HBV
|
Infection
|
Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation .
|
-
-
- HY-124600
-
|
HBV
|
Infection
|
NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .
|
-
-
- HY-151134
-
|
HBV
|
Infection
|
HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA>452 μg/mL) and good PK property with no cellular toxicity .
|
-
-
- HY-149435
-
|
HBV
|
Infection
|
HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM .
|
-
-
- HY-P990015
-
|
HBV
|
Infection
|
Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity .
|
-
-
- HY-16679
-
Helioxanthin 5-4-2
|
HBV
|
Infection
|
Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.
|
-
-
- HY-P99703
-
17.1.41
|
HBV
|
Infection
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
-
-
- HY-N0820
-
-
-
- HY-163516
-
|
HBV
|
Infection
|
HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities .
|
-
-
- HY-109197
-
EYP001
|
FXR
HBV
|
Infection
|
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .
|
-
-
- HY-155547
-
|
HBV
|
Infection
|
HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC50 of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .
|
-
-
- HY-126033
-
|
HBV
RSV
|
Infection
|
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL .
|
-
-
- HY-B1464
-
|
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products .
|
-
-
- HY-149357
-
|
HBV
|
Infection
|
Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .
|
-
-
- HY-13859
-
L-FMAU
|
HBV
DNA/RNA Synthesis
Orthopoxvirus
|
Infection
|
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
|
-
-
- HY-116999
-
|
HBV
|
Infection
|
IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease . HBx: hepatitis B virus X protein.
|
-
-
- HY-B0150
-
Nicotinamide
Maximum Cited Publications
36 Publications Verification
Niacinamide; Nicotinic acid amide
|
Organoid
Endogenous Metabolite
Sirtuin
HBV
|
Cancer
|
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
|
-
-
- HY-B0150A
-
Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride
|
Sirtuin
Endogenous Metabolite
HBV
|
Infection
Cancer
|
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .
|
-
-
- HY-100028
-
AT-130
1 Publications Verification
|
HBV
DNA/RNA Synthesis
|
Infection
Cancer
|
AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells .
|
-
-
- HY-N11792
-
|
Others
|
Others
|
Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC50 value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells .
|
-
-
- HY-N12105
-
|
HBV
|
Infection
|
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC50 values of 1.67 and >2.15 mM, respectively .
|
-
-
- HY-107454
-
|
Sirtuin
HBV
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC50s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects .
|
-
-
- HY-B0150R
-
Niacinamide(Standard); Nicotinic acid amide (Standard)
|
Endogenous Metabolite
Sirtuin
|
Cancer
|
Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
|
-
-
- HY-W063968
-
CDM-3008; RO4948191
|
IFNAR
JAK
STAT
HCV
HBV
|
Infection
|
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
|
-
-
- HY-156665
-
|
HBV
|
Infection
|
HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM .
|
-
-
- HY-16680
-
Helioxanthin analogue 8-1
|
HBV
|
Infection
|
Helioxanthin 8-1 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.
|
-
-
- HY-N3861
-
|
HBV
|
Infection
|
Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor .
|
-
-
- HY-N5086
-
|
HBV
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
Picroside IV is an iridoid glycoside found in the underground parts of Picrorhiza scrophulariiflora. Picroside IV is a derivative of Catalpol (HY-N0820) . Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
|
-
-
- HY-146394
-
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively .
|
-
-
- HY-145060
-
|
HBV
|
Infection
|
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B .
|
-
-
- HY-145053
-
|
HBV
|
Infection
|
HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
|
-
- HY-145053A
-
|
HBV
|
Infection
|
(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
|
-
- HY-147863
-
|
HBV
|
Infection
Neurological Disease
|
HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC50 values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .
|
-
- HY-146395
-
|
HBV
DNA/RNA Synthesis
Apoptosis
|
Infection
Cancer
|
HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis .
|
-
- HY-133721
-
|
HBV
|
Infection
Inflammation/Immunology
|
Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3601
-
FGF basic (1-24)
|
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99608
-
|
HBV
|
Infection
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
-
- HY-P990015
-
|
HBV
|
Infection
|
Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity .
|
-
- HY-P99703
-
17.1.41
|
HBV
|
Infection
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0056
-
3,5-Dicaffeoylquinic acid; 3,5-CQA
|
Structural Classification
Caprifoliaceae
Classification of Application Fields
Lonicera japonica Thunb.
Ketones, Aldehydes, Acids
Source classification
Phenols
Polyphenols
Plants
Endogenous metabolite
Inflammation/Immunology
Disease Research Fields
|
Reactive Oxygen Species
HBV
Endogenous Metabolite
HIV
Bacterial
|
Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with anti-mutagenicity, anti-HBV, anti-HIV, anti-oxidant, anti-bacterial, and anti-inflammatoryy activities .
|
-
-
- HY-N8168
-
-
-
- HY-N10404
-
-
-
- HY-N8153
-
-
-
- HY-N2988
-
-
-
- HY-N1323
-
-
-
- HY-N2192
-
-
-
- HY-123336
-
-
-
- HY-N0820
-
-
-
- HY-126033
-
-
-
- HY-B0150
-
-
-
- HY-B0150A
-
-
-
- HY-N11792
-
-
-
- HY-N12105
-
-
-
- HY-B0150R
-
-
-
- HY-N3861
-
-
-
- HY-N5086
-
-
-
- HY-133721
-
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: